Jen Andre 
- Portfolio News
- 17 December, 2024
Portfolio
Healx secures $56M Series B and launches global accelerator programme for rare diseases
OCT 16, 2019
The round was led by Atomico with participation from Balderton and other existing investors.
The funding will be used to build a clinical-stage portfolio for rare diseases, including treatments for fragile X syndrome, the leading genetic cause of autism. Where the traditional drug discovery model takes more than a decade and can run into the billions of dollars, Healx‘s AI-driven approach makes the process faster, more efficient and more cost-effective. With the launch of the Rare Treatment Accelerator, Healx and partnering patient groups will be able to scale the impact of this approach by leveraging the power of AI and combining their knowledge, information and expertise so that, together, they can discover new treatments and move them towards the clinic within 24 months. Patient communities can apply to join the Rare Treatment Accelerator online.
The trials for our fragile X treatments are just the start of the impact we believe our technology is capable of having on drug discovery. Rare diseases affect over 400 million patients worldwide. Of the 7,000 rare diseases known today, 95% are still without an approved treatment.
The trials for our fragile X treatments are just the start of the impact we believe our technology is capable of having on drug discovery. Rare diseases affect over 400 million patients worldwide. Of the 7,000 rare diseases known today, 95% are still without an approved treatment.
Healx co-founder and CEO, Dr Tim Guilliams
Healx’s Dr Tim Guilliams, CEO and co-founder, Dr Kate Hilyard, COO, and Dr Neil Thompson, CSO.
To date, it’s been families and patient groups who have had to become experts in the diseases affecting their loved ones and have often been the ones driving forward the efforts into finding new treatments. With our unique combination of in-house R&D, industry collaborations and now the Rare Treatment Accelerator, we look forward to supporting these groups in their mission.
To date, it’s been families and patient groups who have had to become experts in the diseases affecting their loved ones and have often been the ones driving forward the efforts into finding new treatments. With our unique combination of in-house R&D, industry collaborations and now the Rare Treatment Accelerator, we look forward to supporting these groups in their mission.
Dr Tim Guilliams
Healx’s mission is to advance 100 rare disease treatments towards the clinic by 2025. Healnet, Healx’s AI platform, delivers data-driven treatment predictions, which shortens the discovery-to-clinic timeline to as little as 24 months.It is the world’s leading AI platform on rare diseases and integrates scientific literature, clinical trial results and proprietary data in the form of a biomedical knowledge graph, pinpointing the potential therapeutic relationships between drugs and diseases.Healx’s multidisciplinary team of rare disease and drug development experts work in concert with Healnet to identify and validate the most promising treatments for a given disease.
Read more on Healx:
